Screener
Discontinued — last reported Q1 '26
EBIT at other companies
Other financials
Where this comes from
Calculated from Tango Therapeutics’s reported figures.
Plus components not separately reported this period.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
FAQ
- What is Tango Therapeutics's EBIT?
- Tango Therapeutics (TNGX) reported EBIT of -$48.77M in Q1 2026.
- How has Tango Therapeutics's EBIT changed year-over-year?
- Tango Therapeutics's EBIT decreased by 14.7% year-over-year, from -$42.53M to -$48.77M.
- What is the long-term trend for Tango Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Tango Therapeutics's EBIT has grown at a 27.1% compound annual growth rate (CAGR), from -$42.59M to -$111.29M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Tango Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude